Geuijen et al. found that TNFRSF9 agonists in combination with PD-L1 effectively activated and amplified tumor-specific cytotoxic T cells; thus, enhancing tumor control and elimination(Geuijen et al., 2021). This evidence concerns the gene TNFRSF9 and neoplasm.